A Study of TAS0728 in Patients With Solid Tumors With HER2 or HER3 Abnormalities
Status:
Active, not recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
This is a First-in-Human (FIH), 2-part, Phase 1/2, open-label, multicenter study design to
evaluate the safety, tolerability, PK, pharmacodynamics, PGx, and efficacy of TAS0728. This
study consists of Phase 1 and Phase 2 components in subjects with advanced solid tumors with
HER2 or HER3 overexpression, amplification, or mutation who have progressed despite standard
therapy or for which no standard therapy exists, particularly urothelial cancer, biliary
tract cancer, metastatic breast cancer, non-small cell lung cancer and colorectal cancer.